Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy

Detalhes bibliográficos
Autor(a) principal: Abrantes,Fabiano Ferreira
Data de Publicação: 2021
Outros Autores: Moraes,Marianna Pinheiro Moraes de, Albuquerque Filho,José Marcos Vieira de, Alencar,Jéssica Monique Dias, Lopes,Alexandre Bussinger, Pinto,Wladimir Bocca Vieira de Rezende, Souza,Paulo Victor Sgobbi de, Oliveira,Enedina Maria Lobato de, Oliveira,Acary de Souza Bulle de, Pedroso,José Luiz, Barsottini,Orlando Graziani Povoas
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021001101012
Resumo: ABSTRACT For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.
id ABNEURO-1_c7e928b8a031e827ccfd3281a5bbe53a
oai_identifier_str oai:scielo:S0004-282X2021001101012
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapyImmunosuppressive AgentsImmunologic FactorsAdrenal Cortex HormonesMultiple SclerosisAutoimmune DiseasesNeurologyABSTRACT For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.Academia Brasileira de Neurologia - ABNEURO2021-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021001101012Arquivos de Neuro-Psiquiatria v.79 n.11 2021reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x-anp-2020-0593info:eu-repo/semantics/openAccessAbrantes,Fabiano FerreiraMoraes,Marianna Pinheiro Moraes deAlbuquerque Filho,José Marcos Vieira deAlencar,Jéssica Monique DiasLopes,Alexandre BussingerPinto,Wladimir Bocca Vieira de RezendeSouza,Paulo Victor Sgobbi deOliveira,Enedina Maria Lobato deOliveira,Acary de Souza Bulle dePedroso,José LuizBarsottini,Orlando Graziani Povoaseng2021-11-17T00:00:00Zoai:scielo:S0004-282X2021001101012Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2021-11-17T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
title Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
spellingShingle Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
Abrantes,Fabiano Ferreira
Immunosuppressive Agents
Immunologic Factors
Adrenal Cortex Hormones
Multiple Sclerosis
Autoimmune Diseases
Neurology
title_short Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
title_full Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
title_fullStr Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
title_full_unstemmed Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
title_sort Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
author Abrantes,Fabiano Ferreira
author_facet Abrantes,Fabiano Ferreira
Moraes,Marianna Pinheiro Moraes de
Albuquerque Filho,José Marcos Vieira de
Alencar,Jéssica Monique Dias
Lopes,Alexandre Bussinger
Pinto,Wladimir Bocca Vieira de Rezende
Souza,Paulo Victor Sgobbi de
Oliveira,Enedina Maria Lobato de
Oliveira,Acary de Souza Bulle de
Pedroso,José Luiz
Barsottini,Orlando Graziani Povoas
author_role author
author2 Moraes,Marianna Pinheiro Moraes de
Albuquerque Filho,José Marcos Vieira de
Alencar,Jéssica Monique Dias
Lopes,Alexandre Bussinger
Pinto,Wladimir Bocca Vieira de Rezende
Souza,Paulo Victor Sgobbi de
Oliveira,Enedina Maria Lobato de
Oliveira,Acary de Souza Bulle de
Pedroso,José Luiz
Barsottini,Orlando Graziani Povoas
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Abrantes,Fabiano Ferreira
Moraes,Marianna Pinheiro Moraes de
Albuquerque Filho,José Marcos Vieira de
Alencar,Jéssica Monique Dias
Lopes,Alexandre Bussinger
Pinto,Wladimir Bocca Vieira de Rezende
Souza,Paulo Victor Sgobbi de
Oliveira,Enedina Maria Lobato de
Oliveira,Acary de Souza Bulle de
Pedroso,José Luiz
Barsottini,Orlando Graziani Povoas
dc.subject.por.fl_str_mv Immunosuppressive Agents
Immunologic Factors
Adrenal Cortex Hormones
Multiple Sclerosis
Autoimmune Diseases
Neurology
topic Immunosuppressive Agents
Immunologic Factors
Adrenal Cortex Hormones
Multiple Sclerosis
Autoimmune Diseases
Neurology
description ABSTRACT For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.
publishDate 2021
dc.date.none.fl_str_mv 2021-11-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021001101012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021001101012
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0004-282x-anp-2020-0593
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.79 n.11 2021
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212789656748032